Tags

Type your tag names separated by a space and hit enter

Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis.
J Clin Psychiatry. 2008 11; 69(11):1732-42.JC

Abstract

OBJECTIVE

Preliminary evidence suggested that sertraline might be slightly superior to other antidepressant medications in terms of efficacy. The aim of this study was to carry out a systematic review and meta-analysis to compare sertraline with any other antidepressant in the acute phase treatment of major depression at 8 weeks.

DATA SOURCES

MEDLINE; EMBASE; the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register; and the Cochrane Central Register of Controlled Trials up to August 2007. No language restriction. The following search strategy was used: diagnosis = depress* or dysthymi* or adjustment disorder* or mood disorder* or affective disorder or affective symptoms, and intervention (or free text) = sertraline. Reference lists of relevant papers and previous systematic reviews were hand-searched. Pharmaceutical companies and experts in this field were contacted for supplemental data.

STUDY SELECTION

Only randomized controlled trials allocating patients with major depression to sertraline versus any other antidepressant agent.

DATA EXTRACTION

Three reviewers independently extracted data. A double-entry procedure was employed by 2 reviewers. To analyze data, a very conservative approach with a 99% confidence interval (CI) and a random effects model was used. Information extracted included study characteristics, participant characteristics, intervention details, and outcome measures, such as the number of patients who responded to treatment and the number of patients who failed to complete the study by any cause at 8 weeks.

DATA SYNTHESIS

This systematic review and meta-analysis found that sertraline is statistically significantly better than fluoxetine (relative risk [RR] = 0.85, 99% CI = 0.74 to 0.98; number needed to treat [NNT] = 12) and other SSRIs as a class (RR = 0.88, 99% CI = 0.78 to 0.99; NNT = 17) and highlighted a consistent even though not statistically significant trend in favor of sertraline over many other antidepressants both in terms of efficacy and acceptability in a homogeneous and clinically relevant time frame of 8 weeks.

CONCLUSIONS

The results of this review suggest that sertraline may be a candidate as the initial choice of antidepressant for people with major depression.

Authors+Show Affiliations

Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Policlinico "G.B. Rossi" Piazzale L.A. Scuro, 10, 37134 Verona, Italy. andrea.cipriani@univr.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Meta-Analysis
Review
Systematic Review

Language

eng

PubMed ID

19026250

Citation

Cipriani, Andrea, et al. "Does Randomized Evidence Support Sertraline as First-line Antidepressant for Adults With Acute Major Depression? a Systematic Review and Meta-analysis." The Journal of Clinical Psychiatry, vol. 69, no. 11, 2008, pp. 1732-42.
Cipriani A, Furukawa TA, Geddes JR, et al. Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. J Clin Psychiatry. 2008;69(11):1732-42.
Cipriani, A., Furukawa, T. A., Geddes, J. R., Malvini, L., Signoretti, A., McGuire, H., Churchill, R., Nakagawa, A., & Barbui, C. (2008). Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. The Journal of Clinical Psychiatry, 69(11), 1732-42.
Cipriani A, et al. Does Randomized Evidence Support Sertraline as First-line Antidepressant for Adults With Acute Major Depression? a Systematic Review and Meta-analysis. J Clin Psychiatry. 2008;69(11):1732-42. PubMed PMID: 19026250.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. AU - Cipriani,Andrea, AU - Furukawa,Toshiaki A, AU - Geddes,John R, AU - Malvini,Lara, AU - Signoretti,Alessandra, AU - McGuire,Hugh, AU - Churchill,Rachel, AU - Nakagawa,Atsuo, AU - Barbui,Corrado, AU - ,, Y1 - 2008/11/04/ PY - 2008/01/08/received PY - 2008/02/28/accepted PY - 2008/11/26/pubmed PY - 2009/3/6/medline PY - 2008/11/26/entrez SP - 1732 EP - 42 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 69 IS - 11 N2 - OBJECTIVE: Preliminary evidence suggested that sertraline might be slightly superior to other antidepressant medications in terms of efficacy. The aim of this study was to carry out a systematic review and meta-analysis to compare sertraline with any other antidepressant in the acute phase treatment of major depression at 8 weeks. DATA SOURCES: MEDLINE; EMBASE; the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register; and the Cochrane Central Register of Controlled Trials up to August 2007. No language restriction. The following search strategy was used: diagnosis = depress* or dysthymi* or adjustment disorder* or mood disorder* or affective disorder or affective symptoms, and intervention (or free text) = sertraline. Reference lists of relevant papers and previous systematic reviews were hand-searched. Pharmaceutical companies and experts in this field were contacted for supplemental data. STUDY SELECTION: Only randomized controlled trials allocating patients with major depression to sertraline versus any other antidepressant agent. DATA EXTRACTION: Three reviewers independently extracted data. A double-entry procedure was employed by 2 reviewers. To analyze data, a very conservative approach with a 99% confidence interval (CI) and a random effects model was used. Information extracted included study characteristics, participant characteristics, intervention details, and outcome measures, such as the number of patients who responded to treatment and the number of patients who failed to complete the study by any cause at 8 weeks. DATA SYNTHESIS: This systematic review and meta-analysis found that sertraline is statistically significantly better than fluoxetine (relative risk [RR] = 0.85, 99% CI = 0.74 to 0.98; number needed to treat [NNT] = 12) and other SSRIs as a class (RR = 0.88, 99% CI = 0.78 to 0.99; NNT = 17) and highlighted a consistent even though not statistically significant trend in favor of sertraline over many other antidepressants both in terms of efficacy and acceptability in a homogeneous and clinically relevant time frame of 8 weeks. CONCLUSIONS: The results of this review suggest that sertraline may be a candidate as the initial choice of antidepressant for people with major depression. SN - 1555-2101 UR - https://www.unboundmedicine.com/medline/citation/19026250/Does_randomized_evidence_support_sertraline_as_first_line_antidepressant_for_adults_with_acute_major_depression_A_systematic_review_and_meta_analysis_ L2 - http://www.psychiatrist.com/jcp/article/pages/2008/v69n11/v69n1108.aspx DB - PRIME DP - Unbound Medicine ER -